0000899243-21-008447.txt : 20210226 0000899243-21-008447.hdr.sgml : 20210226 20210226174731 ACCESSION NUMBER: 0000899243-21-008447 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210224 FILED AS OF DATE: 20210226 DATE AS OF CHANGE: 20210226 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gordon Gary B. CENTRAL INDEX KEY: 0001811354 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39279 FILM NUMBER: 21691882 MAIL ADDRESS: STREET 1: C/O AYALA PHARMACEUTICALS, INC. STREET 2: OPPENHEIMER 4 CITY: REHOVOT STATE: L3 ZIP: 7670104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001797336 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823578375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: (857) 444-0553 MAIL ADDRESS: STREET 1: 1313 N. MARKET STREET STREET 2: SUITE 5100 CITY: WILMINGTON STATE: DE ZIP: 19801 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-24 0 0001797336 Ayala Pharmaceuticals, Inc. AYLA 0001811354 Gordon Gary B. OPPENHEIMER 4 REHOVOT L3 7670104 ISRAEL 0 1 0 0 Chief Medical Officer Common Stock 2021-02-24 4 M 0 3000 5.16 A 11520 D Common Stock 2021-02-24 4 S 0 3000 17.4617 D 8520 D Stock Option 5.16 2021-02-24 4 M 0 3000 0.00 D 2029-09-19 Common Stock 3000 89000 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. This option vested and became exercisable as to 25% of the underlying shares of common stock on August 1, 2020 and will become vested and exercisable as to the remainder of the shares in 12 equal quarterly installments thereafter. /s/ Roni Mamluk, Ph.D., Attorney-in-Fact for Gary B. Gordon 2021-02-26